260 related articles for article (PubMed ID: 10490596)
1. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein.
Fenrick R; Amann JM; Lutterbach B; Wang L; Westendorf JJ; Downing JR; Hiebert SW
Mol Cell Biol; 1999 Oct; 19(10):6566-74. PubMed ID: 10490596
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.
Heibert SW; Lutterbach B; Durst K; Wang L; Linggi B; Wu S; Wood L; Amann J; King D; Hou Y
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S31-4. PubMed ID: 11587363
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of transcriptional repression by TEL/RUNX1 fusion protein.
Lee YJ; Kim JH; Bae S; Rho SK; Choe SY
Mol Cells; 2004 Apr; 17(2):217-22. PubMed ID: 15179033
[TBL] [Abstract][Full Text] [Related]
4. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription.
Hiebert SW; Sun W; Davis JN; Golub T; Shurtleff S; Buijs A; Downing JR; Grosveld G; Roussell MF; Gilliland DG; Lenny N; Meyers S
Mol Cell Biol; 1996 Apr; 16(4):1349-55. PubMed ID: 8657108
[TBL] [Abstract][Full Text] [Related]
5. High incidence of TEL/AML1 fusion resulting from a cryptic t(12;21) in childhood B-lineage acute lymphoblastic leukemia in Taiwan.
Liang DC; Chou TB; Chen JS; Shurtleff SA; Rubnitz JE; Downing JR; Pui CH; Shih LY
Leukemia; 1996 Jun; 10(6):991-3. PubMed ID: 8667657
[TBL] [Abstract][Full Text] [Related]
6. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein.
Lutterbach B; Sun D; Schuetz J; Hiebert SW
Mol Cell Biol; 1998 Jun; 18(6):3604-11. PubMed ID: 9584201
[TBL] [Abstract][Full Text] [Related]
7. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia.
Meyers S; Lenny N; Sun W; Hiebert SW
Oncogene; 1996 Jul; 13(2):303-12. PubMed ID: 8710369
[TBL] [Abstract][Full Text] [Related]
8. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.
Amann JM; Nip J; Strom DK; Lutterbach B; Harada H; Lenny N; Downing JR; Meyers S; Hiebert SW
Mol Cell Biol; 2001 Oct; 21(19):6470-83. PubMed ID: 11533236
[TBL] [Abstract][Full Text] [Related]
9. The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor.
Lutterbach B; Hou Y; Durst KL; Hiebert SW
Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12822-7. PubMed ID: 10536006
[TBL] [Abstract][Full Text] [Related]
10. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.
Shurtleff SA; Buijs A; Behm FG; Rubnitz JE; Raimondi SC; Hancock ML; Chan GC; Pui CH; Grosveld G; Downing JR
Leukemia; 1995 Dec; 9(12):1985-9. PubMed ID: 8609706
[TBL] [Abstract][Full Text] [Related]
11. TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines.
Kim DH; Moldwin RL; Vignon C; Bohlander SK; Suto Y; Giordano L; Gupta R; Fears S; Nucifora G; Rowley JD
Blood; 1996 Aug; 88(3):785-94. PubMed ID: 8704231
[TBL] [Abstract][Full Text] [Related]
12. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.
Wang J; Hoshino T; Redner RL; Kajigaya S; Liu JM
Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10860-5. PubMed ID: 9724795
[TBL] [Abstract][Full Text] [Related]
13. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein.
Melnick A; Carlile GW; McConnell MJ; Polinger A; Hiebert SW; Licht JD
Blood; 2000 Dec; 96(12):3939-47. PubMed ID: 11090081
[TBL] [Abstract][Full Text] [Related]
14. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors.
Lutterbach B; Westendorf JJ; Linggi B; Patten A; Moniwa M; Davie JR; Huynh KD; Bardwell VJ; Lavinsky RM; Rosenfeld MG; Glass C; Seto E; Hiebert SW
Mol Cell Biol; 1998 Dec; 18(12):7176-84. PubMed ID: 9819404
[TBL] [Abstract][Full Text] [Related]
15. Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein.
Guidez F; Petrie K; Ford AM; Lu H; Bennett CA; MacGregor A; Hannemann J; Ito Y; Ghysdael J; Greaves M; Wiedemann LM; Zelent A
Blood; 2000 Oct; 96(7):2557-61. PubMed ID: 11001911
[TBL] [Abstract][Full Text] [Related]
16. TEL/AML1 shows dominant-negative effects over TEL as well as AML1.
Gunji H; Waga K; Nakamura F; Maki K; Sasaki K; Nakamura Y; Mitani K
Biochem Biophys Res Commun; 2004 Sep; 322(2):623-30. PubMed ID: 15325275
[TBL] [Abstract][Full Text] [Related]
17. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
Stams WA; den Boer ML; Beverloo HB; Meijerink JP; van Wering ER; Janka-Schaub GE; Pieters R
Clin Cancer Res; 2005 Apr; 11(8):2974-80. PubMed ID: 15837750
[TBL] [Abstract][Full Text] [Related]
18. Analysis of TEL proteins in human leukemias.
Poirel H; Lacronique V; Mauchauffé M; Le Coniat M; Raffoux E; Daniel MT; Erickson P; Drabkin H; MacLeod RA; Drexler HG; Ghysdael J; Berger R; Bernard OA
Oncogene; 1998 Jun; 16(22):2895-903. PubMed ID: 9671410
[TBL] [Abstract][Full Text] [Related]
19. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia.
Cayuela JM; Baruchel A; Orange C; Madani A; Auclerc MF; Daniel MT; Schaison G; Sigaux F
Blood; 1996 Jul; 88(1):302-8. PubMed ID: 8704188
[TBL] [Abstract][Full Text] [Related]
20. Lack of TEL-AML1 fusion transcript resulting from a cryptic t(12;21) in adult B lineage acute lymphoblastic leukemia in Taiwan.
Shih LY; Chou TB; Liang DC; Tzeng YS; Rubnitz JE; Downing JR; Pui CH
Leukemia; 1996 Sep; 10(9):1456-8. PubMed ID: 8751462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
